MS
KDNY

Maven Securities’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Maven Securities’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-28,269
Closed -$461K – 1156
2021
Q4 		$461K Buy
+28,269
New +$402K 0.01% 582
2021
Q3 		– Sell
-34,777
Closed -$494K – 1350
2021
Q2 		$494K Buy
+34,777
New +$556K 0.02% 667

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Maven Securities's KDNY Position: Q1 2022 in Review

Maven Securities sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2022, closing a stake of 28,269 shares — an estimated $461K sold.

Maven Securities first reported a position in KDNY in Q2 2021 and held it in 2 quarters. The position peaked at $494K in Q2 2021. 105 funds tracked by Wall St. Rank hold KDNY as of Q1 2022.

  • Maven Securities reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Maven Securities sold 28,269 Chinook Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $461K.
  • Maven Securities first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Maven Securities's Chinook Therapeutics, Inc. Common Stock position peaked at $494K in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Maven Securities's 13F filing for Q1 2022, filed 16 May 2022.